Trials Sponsors Conditions Drugs Pricing

Conditions

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Keywords

CAR-T Cells targeting Igβ targetsRelapsed Refractory B-cell Non-Hodgkin's Lymphoma

Outcome Measures

Primary Outcomes (2)

DLT
DLT occurring within 28 days of the last dose.
Measured from start of treatment until 28 days after last dose
Adverse events profile
Number of participants with adverse events. Frequencies of toxicities based on the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 will be tabulated.
Measured from start of treatment until 28 days after last dose

Secondary Outcomes (8)

Objective Response Rate
up to 3 months
Duration of Response
up to 12 months
Progression-free survival
up to 12 months
Overall Survival
up to 12 months
Peak Plasma Concentration
Measured from start of treatment until 28 days after last dose
+3 more secondary outcomes

Study Arms (1)

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

EXPERIMENTAL

Chimeric antigen receptor T cells targeting Igβ targets (CAR-T)

Drug: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Interventions

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ TargetsDrug

1. Dose escalation studies:3 dose groups in total: expect 3-6 cases in each group, and dose set at 1×106/kg，3×106/kg，6×106/kg. 2. Dose extension study:3 cases (1 dose group).

Also known as: Chimeric antigen receptor-modified T (CAR-T) cell therapy

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age6 Years+

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Voluntary signing of informed consent and good compliance.
Age ≥ 6 years.

Sponsors & Collaborators

The First Affiliated Hospital of Soochow University
Otherlead

Study Sites (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215000, China

MeSH Terms

Conditions

Lymphoma, B-Cell

Interventions

Immunotherapy, AdoptiveCell- and Tissue-Based Therapy

Condition Hierarchy (Ancestors)

Lymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Study Officials

Depei Wu, M.D
The First Affiliated Hospital of Soochow University
STUDY CHAIR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 21, 2022

First Posted

April 5, 2022

Study Start

May 26, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Stopped

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (8)

Study Arms (1)

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (8)

Study Arms (1)

Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations